Industry Press Releases

IMBRUVICA® (ibrutinib) receives expanded approval for treatment of Waldenstrom's macroglobulinemia

Friday, Jan 30, 2015
Pressreleases

Diplomat Pharmacy, Inc. (DPLO), the nation's largest independent specialty pharmacy, announced today that the U.S. Food and Drug Administration has approved an expanded indication of IMBRUVICA® (ibrutinib) for the treatment of Waldenstrom's macroglobulinemia (WM). The drug was granted expanded approval under the breakthrough therapy designation.

WM is a type of non-Hodgkin lymphoma that begins in the body's immune system. For patients living with WM, abnormal blood cells grow within bone marrow, lymph nodes, liver and spleen which then overproduce a protein known as immunoglobulin M. IMBRUVICA® treats the disease by blocking the enzyme that supports the growth and division of the abnormal blood cells. According to the American Cancer Society, 1,000–5,000 cases of WM are diagnosed each year, with the average age of diagnosis in the mid-60s.

"We are pleased to continue to be a part of the narrow distribution network for IMBRUVICA®," said Gary Kadlec, president of Diplomat. "The expanded indication will allow Diplomat to provide care and support for a previously underserved patient population. Our high-touch model and patient-centric approach to care supports our commitment to administering this therapy in accordance with our high standards."

Diplomat is currently distributing IMBRUVICA® for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. IMBRUVICA® was approved by the FDA in November 2013 under the breakthrough therapy designation for the treatment of MCL in patients who have received prior therapy for the disease. IMBRUVICA® was granted expanded approval for the treatment of CLL in patients who have received at least one prior therapy for the disease in February 2014 and for treatment of CLL in patients with 17p deletion in July 2014.

 

Source : http://finance.yahoo.com/

Other Press Releases